The 2024 impact factor is approximately 2.6 according to Web of Science and corroborated by multiple databases. The 5-year impact factor is higher, around 3.2—a nod to how articles mature over time.
But here’s the fun part: PLOS doesn’t lead with that number. In fact, their journal information page flat-out says they don’t consider impact factor a reliable marker for individual articles—and they’d rather you look at more nuanced metrics like Article-Level Metrics (ALMs), SJR, CiteScore, or h-index.
Nope. You won't spot a badge plastered on their website saying *“Our IF is awesome!”*. Instead, they steer you toward metrics that reflect the value of each paper:
In fact, their open-science philosophy is sort of like a chef saying, “Taste it yourself,” rather than showing you Yelp stars.
Now, if you're comparing to giants like Nature or Cell, sure, an IF of ~2.6 seems modest. But for a mega-journal pumping out thousands of papers every year? That’s not shabby.
Let’s dig into the trend:
Year | Impact Factor (IF) |
---|---|
2022 | ~3.7 |
2023 | ~2.9 |
2024 | ~2.6 |
You can see that it's dipped a bit recently (Bioxbio, Resurchify).
Here’s the catch: bigger journals like this simply can’t sustain ultra-high IFs because the sheer volume of articles “dilutes” the average, regardless of individual quality.
PLOS ONE was once riding high—with early IFs over 3, even close to 4. But as it grew, the average naturally drifted lower.
Surprisingly, it’s not just by letting anything through.
So, when someone asks, *“How does PLOS ONE maintain its impact factor?”*, part of the answer lies in this interplay of quality control, access, and sheer scale.
Ah, the ever-popular Q1 vs Q2 question—often applied to rankings by discipline.
According to SCImago, PLOS ONE’s SJR for 2024 is 0.803, and it's classified as Q1 in the Multidisciplinary category.
Yet, when you look at Web of Science, the Percentile Rank across all Multidisciplinary Sciences is about 67.4%, which puts it solidly high—but maybe not elite.
In short: in some disciplines it’s Q1; in others, maybe Q2 depending on the field and database.
This question pops up mostly because of misunderstandings around open access and fees. PLOS ONE:
Basically, it’s legit—and the fees support an open-access model and editorial infrastructure, not vanity publishing.
This is where some folks raise eyebrows—but transparency helps.
It's not cheap—but it’s straightforward, and institutional agreements can offset the cost.
PLOS ONE publishes all scientifically sound research regardless of perceived impact, provided the methodology is solid. Article types include:
Because PLOS ONE’s scope is so broad, you’ll see everything from molecular biology to social science in the same issue. It’s multidisciplinary by design.
Technically, there’s no strict page limit. PLOS ONE accepts long manuscripts as long as they are clear, well-structured, and scientifically justified.
So if your paper needs extra space to fully describe experiments or data, that’s usually fine.
Here’s the thing: IF is like judging a buffet by the average taste of every dish on the table. It gives you a snapshot—but misses the marquee items that stand out.
For early-career researchers, IF can matter. Committees, funders, and institutions still look at it. But the smarter move? Focus on article-level metrics: downloads, citations, Altmetric attention—each paper’s story counts.
PLOS has nudged this narrative for years, aligning with broader pushes like **DORA (San Francisco Declaration on Research Assessment)**.
You know what? It’s freeing to say: PLOS ONE is not elite, and that’s okay. You’re getting:
Sure, if you're only chasing prestige, you might go elsewhere. But if you're after visibility, real science, and a platform where your paper matters on its own terms—PLOS ONE is solid.
About 2.6, with a 5-year IF around 3.2, per Web of Science.
It’s Q1 in SCImago for Multidisciplinary Science (SJR = 0.803), but can appear as Q2 in certain Web of Science categories.
$2,382 USD for most research articles, with waivers and institutional discounts available.
No. It’s fully indexed (PubMed, Scopus, WoS), rigorously peer-reviewed, and transparent about editorial practices.
It peaked around **3.7 (2022), dropped to 2.9 (2023)**, then to 2.6 (2024) as mega-journal growth naturally diluted citation averages.
Anything scientifically sound: research articles, systematic reviews, protocols, data notes, registered reports—across all disciplines.
No strict limit. Most fall between 3,000–7,000 words, but longer papers are accepted if well-justified. Supplementary data is unrestricted.
If you found this breakdown helpful, PubMed.ai offers AI-powered tools to help researchers, students, and clinicians quickly summarize biomedical literature, track citation metrics, and explore related studies without wading through endless search results. Whether you’re analyzing journal impact factors or diving into drug safety profiles, PubMed.ai streamlines your workflow with precision and speed.
Recommended reads from the PubMed.ai Blog:
Have a question about medical research, clinical practice, or evidence-based treatment? Access authoritative, real-time insights: PubMed.ai is an AI-Powered Medical Research Assistant.